H-Index
34
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
call: +1.631.629.4327
Mon-Fri 10 am - 2 pm EST

Logo

MSMbanner
Medical Science Monitor Basic Research

AmJCaseRep
MedSciTechnol

eISSN: 2329-0358

C1q Test for Identification of Sensitized Liver Recipients at Risk of Early Acute Antibody-Mediated Rejection

Tomasz Kozlowski, Eric T. Weimer, Kenneth Andreoni, John Schmitz

Department of Surgery, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Ann Transplant 2017; 22:518-523

DOI: 10.12659/AOT.904867

Available online:

Published: 2017-08-25


#904867

BACKGROUND: The majority of liver recipients transplanted with positive crossmatch have a post-transplant course free of acute antibody-mediated rejection (AMR). However, 10% of sensitized recipients develop early severe AMR. There is no clear strategy that would allow for predicting the postoperative course in sensitized liver recipients. One of the possible factors contributing to the dichotomous course in sensitized recipients may be the complement-binding characteristics of the donor-specific antibodies (DSA).
MATERIAL AND METHODS: We tested sera of sensitized recipients with DSA at the time of transplant, diagnosed with severe AMR or ‘AMR-free’ for C1q reactivity and strength of mean fluorescence intensity (MFI) in single-antigen beads (SAB) assay.
RESULTS: Both groups tested positive for DSA C1q binding and DSA-SAB. Recipients with early AMR had significantly stronger DSA MFI in the C1q assay (P<.0001). AMR was observed in patients with very high DSA C1q MFI (22681±8841 vs. the no-AMR group 7954±2061). In SAB assay, DSA MFI strength differences were equivocal (P=0.31).
CONCLUSIONS: The C1q test is a supportive adjunct in identifying patients at risk of postoperative acute AMR and selects an AMR-free course with 100% negative predictive value despite the presence of DSA.

Keywords: Allografts, Graft Rejection, Liver Transplantation



Back